<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Facioscapulohumeral muscular dystrophy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Facioscapulohumeral muscular dystrophy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Facioscapulohumeral muscular dystrophy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Basil T Darras, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 19, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H263587870">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in several genes required for normal muscle function. Some of the genes responsible for these conditions have been identified. Muscle weakness is the primary symptom.
        </p>
        <p>
         Facioscapulohumeral muscular dystrophy (FSHD) is the third most common type of muscular dystrophy. It is a complex genetic disorder characterized in most cases by slowly progressive muscle weakness involving the facial, scapular, upper arm, lower leg, and hip girdle muscles, usually with asymmetric involvement.
        </p>
        <p>
         The clinical aspects of facioscapulohumeral muscular dystrophies are discussed here. Other muscular dystrophies are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/6149.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6185.html" rel="external">
          "Emery-Dreifuss muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">
          "Oculopharyngeal, distal, and congenital muscular dystrophies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H263594296">
         <span class="h1">
          ETIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3944242591">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of FSHD is inappropriate expression of the double homeobox protein 4 gene (
         <em>
          DUX4
         </em>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. The
         <em>
          DUX4
         </em>
         gene lies within each unit of a macrosatellite array known as D4Z4, located in the 4q35 region. The
         <em>
          DUX4
         </em>
         gene is normally expressed in germ line tissue but is epigenetically repressed in somatic cells [
         <a href="#rid3">
          3
         </a>
         ]. Release of
         <em>
          DUX4
         </em>
         repression (derepression) only occurs in the context of a permissive genetic background.
        </p>
        <p>
         There are two genetically distinct forms of FSHD, FSHD1, and FSHD2, which are caused by the inappropriate expression of
         <em>
          DUX4
         </em>
         [
         <a href="#rid4">
          4
         </a>
         ]. Different pathways, including the D4Z4 repeat number in FSHD1 and heterozygous pathogenic
         <em>
          SMCHD1
         </em>
         variants in FSHD2, result in D4Z4 chromatin relaxation and abnormal expression of
         <em>
          DUX4
         </em>
         .
        </p>
        <p>
         Both FSHD1 and FSHD2 require the polyadenylation signal provided by a permissive 4qA haplotype [
         <a href="#rid5">
          5
         </a>
         ]. The polyadenylated
         <em>
          DUX4
         </em>
         transcripts remain stable and lead to the development of FSHD by a toxic gain-of-function mechanism  (
         <a class="graphic graphic_figure graphicRef50217" href="/z/d/graphic/50217.html" rel="external">
          figure 1
         </a>
         ). In the absence of polyadenylation,
         <em>
          DUX4
         </em>
         transcripts are unstable, and FSHD does not develop.
        </p>
        <p class="headingAnchor" id="H2774579039">
         <span class="h2">
          FSHD1
         </span>
         <span class="headingEndMark">
          —
         </span>
         In approximately 95 percent of patients with FSHD, the disorder is causally related to a short repeat array that remains after deletion of an integral number of tandemly arrayed 3.3 kb repeat units (called D4Z4) in the 4q35 region  (
         <a class="graphic graphic_figure graphicRef129048" href="/z/d/graphic/129048.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid6">
          6-8
         </a>
         ]. The number of D4Z4 repeat units in the general population varies from 11 to 100. In patients with FSHD1, one D4Z4 allele is contracted (1 to 10 repeat units), and the other D4Z4 allele has the normal number (11 to 100 repeat units). Contracted D4Z4 repeat arrays are associated with DNA hypomethylation, favoring a more relaxed chromatin structure, which facilitates stable expression of the myotoxic
         <em>
          DUX4
         </em>
         with a 4qA permissive haplotype [
         <a href="#rid2">
          2,9,10
         </a>
         ]. In a retrospective cohort study of over 800 patients with FSHD1, the degree of 4q35 distal D4Z4 hypomethylation was correlated with disease severity and progression [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         There is a rough and inverse relationship between the onset and clinical severity of FSHD, and the size of the pathogenic (contracted) D4Z4 repeat array. Individuals with one to three repeat D4Z4 units are typically at the severe end of the disease spectrum and usually present as “infantile” cases with severe weakness and a higher incidence of extramuscular manifestations (see
         <a class="local">
          'Infantile form'
         </a>
         below). In patients with one to six repeats, the repeat number correlates inversely with disease severity. With 7 to 10 repeat units, the clinical variation ranges from asymptomatic to severely affected and nonpenetrance (no signs of FSHD on examination) is more common [
         <a href="#rid1">
          1,2
         </a>
         ]. Only approximately one-half of the contractions of the D4Z4 repeat array to a size of 1 to 10 units are pathogenic, as the array needs to reside on an FSHD-permissive genetic background of chromosome 4 that contains a polymorphic polyadenylation signal for DUX4 [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3191163836">
         <span class="h2">
          FSHD2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 5 percent of patients with FSHD have no contracted D4Z4 repeat array but show DNA hypomethylation on both normal D4Z4 alleles [
         <a href="#rid9">
          9
         </a>
         ], a condition termed FSHD2. Patients with FSHD2 typically have a lower number of D4Z4 repeats, ranging from 11 to 20, compared with 11 to 100 repeats in the general population [
         <a href="#rid13">
          13
         </a>
         ]. Heterozygous pathogenic variants in
         <em>
          SMCHD1
         </em>
         , a chromatin modifier gene, are the cause of most cases of FSHD2 via D4Z4 chromatin relaxation [
         <a href="#rid14">
          14
         </a>
         ]. The SMCHD1 protein is an epigenetic modifier that directly binds to the D4Z4 repeat to maintain a repressed chromatin state in somatic cells via methylation, and its reduced activity in FSHD2 patients leads to hypomethylation of the D4Z4 repeat array and thus the derepression of DUX4 transcription [
         <a href="#rid15">
          15,16
         </a>
         ]. Other causes of FSHD2 include rare pathogenic variants of
         <em>
          DNMT3B
         </em>
         and
         <em>
          LRIF1
         </em>
         genes that lead to chromatin relaxation [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         The phenotype of FSHD2 appears to be clinically indistinguishable from FSHD1 [
         <a href="#rid19">
          19
         </a>
         ]. Patients with both 8 to 10 D4Z4 repeats (FSHD1) and a pathogenic variant in the SMCHD1 gene (FSHD2) are more severely affected compared with affected family members who have only one of the two pathogenic variants [
         <a href="#rid15">
          15,16,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H113149776">
         <span class="h2">
          Inheritance pattern
         </span>
         <span class="headingEndMark">
          —
         </span>
         The inheritance pattern of FSHD1 is autosomal dominant [
         <a href="#rid6">
          6
         </a>
         ]. However, sporadic occurrences are frequent, as de novo pathogenic contraction variants of the D4Z4 locus account for 10 to 30 percent of FSHD1 cases [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p>
         The inheritance of FSHD2 is digenic, requiring a pathogenic variant in a chromatin modifier gene and a borderline-sized D4Z4 repeat array on a permissive 4qA haplotype [
         <a href="#rid2">
          2,14
         </a>
         ]. Although data are limited, approximately 60 percent of FSHD2 cases appear to be sporadic [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H263594875">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The estimated prevalence of FSHD is 4 to 12 per 100,000 population [
         <a href="#rid23">
          23-26
         </a>
         ]; a study from the Netherlands found an incidence of 0.3 per 100,000 person-years [
         <a href="#rid26">
          26
         </a>
         ]. FSHD is the third most common type of muscular dystrophy, behind only the dystrophinopathies (Duchenne and Becker muscular dystrophies) and myotonic dystrophy [
         <a href="#rid7">
          7,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6149.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H263587884">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H3050557860">
         <span class="h2">
          Disease onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         The age of symptom onset varies from infancy to middle age but is usually in the second decade. By age 20 years, findings are seen in approximately 90 percent of affected patients [
         <a href="#rid6">
          6
         </a>
         ], although some or all of the signs may be subclinical [
         <a href="#rid27">
          27
         </a>
         ]. Progression is usually slow with a normal or near-normal life span. However, disease severity is also highly variable. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H611110">
         <span class="h2">
          Muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         The typical or classic form of FSHD is characterized by muscle weakness involving the facial, scapular, upper arm, lower leg, and abdominal muscles, usually with asymmetric involvement  (
         <a class="graphic graphic_figure graphicRef141405" href="/z/d/graphic/141405.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid6">
          6,27,28
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Facial involvement
         </strong>
         – The facial muscles are involved initially, in some cases with inability to close the eyes tightly, smile, or whistle, with a pouting appearance of the lips, an expressionless face, and mild dimpling in the areas lateral to the angles of the mouth  (
         <a class="graphic graphic_picture graphicRef141403" href="/z/d/graphic/141403.html" rel="external">
          picture 1
         </a>
         ). However, the facial weakness can be mild early in the course and may remain mild for many years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dysphagia is rare in patients with FSHD but can develop due to weakness of the jaw and lingual muscles [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shoulders and upper arms
         </strong>
         – Weakness of the shoulder and upper arm muscles is characteristic [
         <a href="#rid6">
          6,27
         </a>
         ]. Scapular winging is a common early feature. A distinctive appearance of the shoulders can develop  (
         <a class="graphic graphic_picture graphicRef141404" href="/z/d/graphic/141404.html" rel="external">
          picture 2
         </a>
         ) with protrusion of the trapezii muscles, riding of the scapulae upwards and over the lateral parts of the thorax, and forward jutting of the medial ends of the clavicles when the arms are abducted. The deltoid muscles are relatively spared in the early stages and are relatively less affected compared with other shoulder girdle muscles as the disease progresses. By contrast, the pectoral muscles are severely affected with weakness and atrophy [
         <a href="#rid30">
          30
         </a>
         ]. There is also marked weakness and atrophy of the biceps and triceps, while forearm muscles are usually spared.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower body
         </strong>
         – Weakness of the lower abdominal muscles is often present, leading to a protuberant abdomen, an exaggerated lumbar lordosis, and a positive Beevor sign, characterized by upward deflection of the umbilicus with neck flexion in supine position  (
         <a class="graphic graphic_movie graphicRef141402" href="/z/d/graphic/141402.html" rel="external">
          movie 1
         </a>
         ) [
         <a href="#rid6">
          6,27
         </a>
         ]. The lower leg (peroneal) muscles are variably affected in FSHD, resulting in foot drop. In addition, there can be associated hip girdle weakness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory function
         </strong>
         – Respiratory function is usually but not always preserved. A Dutch population-based study reported that respiratory insufficiency requiring nocturnal ventilatory support affected approximately 1 percent of patients with FSHD [
         <a href="#rid31">
          31
         </a>
         ], while a cross-sectional observational study of 69 patients with FSHD found that restrictive lung disease by pulmonary function testing was present in approximately 10 percent [
         <a href="#rid32">
          32
         </a>
         ]. One case-control study of 14 adults with FSHD and 14 matched controls found that both the diaphragm and expiratory abdominal muscles were weak in the FSHD group compared with the control group [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients are at risk for sleep-related breathing disorders. In a study of adults with FSHD admitted to a sleep laboratory complaining of morning headaches, excessive daytime sleepiness, or other sleep-related symptoms, nocturnal hypoventilation and obstructive sleep apnea were common findings [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H611117">
         <span class="h2">
          Other manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other manifestations of FSHD may include pain, retinal vasculopathy, hearing loss, cardiac arrhythmia, cognitive impairment, and epilepsy [
         <a href="#rid6">
          6,27
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pain
         </strong>
         – Chronic pain affects 55 to 80 percent of patients with FSHD, with severe pain in up to 23 percent [
         <a href="#rid35">
          35-38
         </a>
         ]. The most common locations for pain include the shoulder, neck, lower back, and lower legs. The pathophysiology of pain in FSHD is likely multifactorial, including contributions from myalgias and from biomechanical stress related to muscle weakness and postural problems such as kyphosis and lordosis [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retinal vasculopathy
         </strong>
         – Vision is typically normal in FSHD despite the presence of retinal vascular disease, which occurs in 50 to 75 percent of patients [
         <a href="#rid40">
          40,41
         </a>
         ]. The retinal vasculopathy is characterized by bilateral retinal telangiectasias and microaneurysms as demonstrated by
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          fluorescein
         </a>
         angiography. Rare patients with FSHD demonstrate retinal telangiectasia and exudation that can progress to retinal detachment and visual loss, a condition known as Coats disease when unilateral and idiopathic [
         <a href="#rid42">
          42,43
         </a>
         ]. Coats syndrome associated with FSHD can be bilateral [
         <a href="#rid44">
          44
         </a>
         ]. Visual acuity loss affects approximately 1 percent of patients with FSHD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hearing loss
         </strong>
         – Progressive hearing loss may occur with an increased prevalence in FSHD compared with the general population and is described in both typical and particularly in severe infantile cases [
         <a href="#rid40">
          40,45,46
         </a>
         ]. Hearing loss in children with FSHD appears to correlate with larger D4Z4 repeat contraction size (ie, smaller EcoRI/BlnI fragment size) [
         <a href="#rid46">
          46
         </a>
         ]. However, other studies have failed to corroborate an increased rate of hearing loss in FSHD [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac function
         </strong>
         – Cardiac arrhythmias, generally asymptomatic, probably have a higher prevalence in FSHD compared with the general population as reported by several studies [
         <a href="#rid49">
          49-52
         </a>
         ] but not all [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cognition
         </strong>
         – Cognitive impairment, sometimes with epilepsy, has been reported in patients with severe early-onset FSHD [
         <a href="#rid54">
          54-57
         </a>
         ]. (See
         <a class="local">
          'Infantile form'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H465985">
         <span class="h2">
          Atypical forms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetically confirmed variants (with contraction of the D4Z4 macrosatellite repeat in the subtelomeric region of chromosome 4q35) of FSHD include the following types:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infantile (early onset) form (see
         <a class="local">
          'Infantile form'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scapulohumeral dystrophy phenotype with facial sparing [
         <a href="#rid58">
          58-61
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb-girdle muscular dystrophy phenotype [
         <a href="#rid62">
          62
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Distal myopathy [
         <a href="#rid58">
          58,62,63
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal monomelic lower limb or upper limb atrophy [
         <a href="#rid64">
          64,65
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axial myopathy with camptocormia [
         <a href="#rid66">
          66-68
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The phenotypic spectrum of FSHD may continue to expand with the ability to confirm the diagnosis by molecular genetic testing.
        </p>
        <p class="headingAnchor" id="H263595706">
         <span class="h3">
          Infantile form
         </span>
         <span class="headingEndMark">
          —
         </span>
         The infantile variety of FSHD, which is often sporadic in inheritance, is observed in approximately 4 percent of patients with FSHD [
         <a href="#rid69">
          69,70
         </a>
         ]. The onset is within the first few years of life and the course is rapidly progressive in most cases, with wheelchair confinement by the age of 12 years or earlier. Children with this form of FSHD develop early facial weakness, with an inability to close the eyes in sleep, and inability to smile or show facial expression. The weakness soon involves the shoulder and hip girdles resulting in severe lumbar lordosis, pronounced forward pelvic tilt, and hyperextension of the knees and the head upon walking. Marked weakness of the wrist extensors may result in a wrist drop.
        </p>
        <p>
         While infantile FSHD is usually associated with severe limb weakness and marked disability, rare cases manifest with milder limb weakness – despite severe facial diplegia – and retained ability to ambulate [
         <a href="#rid70">
          70-73
         </a>
         ].
        </p>
        <p>
         Young children with early onset FSHD and a very small number of chromosome 4q35 repeats often have epilepsy, intellectual disability, and severe sensorineural hearing loss [
         <a href="#rid54">
          54,74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H263587905">
         <span class="h2">
          Laboratory abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum creatine kinase is often but not always elevated in patients with symptomatic FSHD, usually to no more than five times the upper limit of normal [
         <a href="#rid6">
          6
         </a>
         ]. Creatine kinase is rarely elevated in asymptomatic patients.
        </p>
        <p>
         The EMG typically displays myopathic features with low amplitude, short duration, polyphasic potentials. (See
         <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">
          "Overview of electromyography", section on 'Myopathies'
         </a>
         .)
        </p>
        <p>
         The muscle biopsy shows mainly nonspecific myopathic changes, with variability in fiber size including large hypertrophic fibers and a few angulated atrophic fibers. In addition, inflammatory cell infiltrates are present in up to 40 percent of patients with FSHD [
         <a href="#rid6">
          6,27
         </a>
         ]. The inflammation is usually mild but may be intense. Histological differentiation from polymyositis is based upon the fact that hypertrophy of the muscle fibers is not observed in the myositis. (See
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H263587912">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of typical (classic) FSHD is suspected in patients who present with weakness of the face, shoulder girdle, and upper arm with relative sparing of the deltoid muscles [
         <a href="#rid75">
          75
         </a>
         ]. Genetic testing is the principle method for confirming the diagnosis  (
         <a class="graphic graphic_algorithm graphicRef103638" href="/z/d/graphic/103638.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid6">
          6,27,76,77
         </a>
         ]. However, genetic testing is not necessary for each affected person with a typical clinical presentation if the family history is consistent with autosomal dominant inheritance and the diagnosis has been genetically confirmed in a first-degree relative [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In general, patients with suspected muscular dystrophy should be referred to a specialist with expertise in neuromuscular disorders (where available) for evaluation and diagnosis.
        </p>
        <p class="headingAnchor" id="H87347354">
         <span class="h2">
          Clinical diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of typical FSHD is suspected in patients who present with relatively selective weakness of the face and shoulder girdle muscles, typically including weakness of the scapular fixators with scapular winging [
         <a href="#rid75">
          75
         </a>
         ]. In occasional FSHD cases where symptomatic lower leg or hip girdle weakness leads to presentation, there is nearly always some degree of face and shoulder girdle involvement on clinical examination. (See
         <a class="local">
          'Muscle weakness'
         </a>
         above.)
        </p>
        <p>
         The clinical diagnostic criteria for FSHD, proposed in the 1990s, have been largely supplanted by molecular genetic testing [
         <a href="#rid27">
          27
         </a>
         ]. The relevance of these criteria is challenged by the finding that some patients with a confirmed genetic diagnosis of FSHD do not fulfill the clinical criteria [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Electromyography (EMG) and muscle biopsy are not necessary when the diagnosis of FSHD is confirmed by genetic testing. However, EMG and muscle biopsy (see
         <a class="local">
          'Laboratory abnormalities'
         </a>
         above) are suggested for patients with a clinical suspicion of FSHD who have negative standard genetic testing for FSHD1 and FSHD2 [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Limited data suggest that a positive Beevor sign has a high sensitivity and specificity for FSHD. In one prospective case-control study, a Beevor sign was present in 27 of 30 patients (90 percent) with FSHD, and was absent in 40 control patients with other neuromuscular disorders [
         <a href="#rid78">
          78
         </a>
         ]. A later unblinded case-control study found a positive Beevor sign in 19 of 20 patients (95 percent) with FSHD, 2 of 28 patients (7 percent) with other neuromuscular disorders, and 0 of 20 control patients without muscle disease [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         Inspection of the extensor digitorum brevis (EDB) muscle is helpful in the diagnosis of FSHD, because it is usually hypertrophic. By comparison, atrophy of the EDB muscle is common in peripheral motor neuropathies.
        </p>
        <p class="headingAnchor" id="H87347347">
         <span class="h2">
          Genetic confirmation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A commercial genetic test for FSHD uses a p13E-11 DNA probe to detect a specific deletion of a tandem array of 3.3 kb repeated DNA elements (D4Z4) that is located within the subtelomere region of chromosome 4q (4q35). This diagnostic test is positive in approximately 95 percent of typical FSHD1 cases [
         <a href="#rid80">
          80-82
         </a>
         ].
        </p>
        <p>
         When the clinical suspicion for FSHD is high, a positive genetic test is sufficient to confirm the diagnosis of FSHD1 and further testing to exclude a false positive result is generally not necessary [
         <a href="#rid76">
          76
         </a>
         ]. However, if the genetic test for the D4Z4 repeat array contraction is negative, genetic testing of the
         <em>
          SMCHD1
         </em>
         gene for FSHD2 should be pursued along with haplotype and methylation analysis [
         <a href="#rid83">
          83
         </a>
         ]. In these patients, if
         <em>
          SMCHD1
         </em>
         gene testing is negative, pathogenic variants in
         <em>
          DNMT3B
         </em>
         and
         <em>
          LRIF1
         </em>
         should be considered as a rare cause of the disease [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         A number of issues can complicate the genetic diagnosis of FSHD and lead to a false negative or false positive result [
         <a href="#rid6">
          6,76
         </a>
         ]. Some of the more important issues include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A false negative result can occur when there is proximal deletion of DNA sequences encompassing the diagnostic probe region p13E-11 that prevents the detection of a mutation in a patient with FSHD [
         <a href="#rid84">
          84
         </a>
         ]. In cases with a typical FSHD phenotype that have negative standard DNA testing with the p13E-11 probe, a more detailed genetic evaluation is needed to look for a contracted 4q35 D4Z4 repeat array [
         <a href="#rid85">
          85-87
         </a>
         ]. Proximally extended deletions that carry a p13E-11 deletion can be detected by using additional probes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A false negative result can occur with an epigenetic variant called FSHD2, which is
         <strong>
          not
         </strong>
         associated with D4Z4 repeat contractions but does require at least one permissive 4qA allele and profound DNA hypomethylation on both normal D4Z4 alleles (see
         <a class="local">
          'Etiology'
         </a>
         above). FSHD2 accounts for approximately 3 percent of all cases of FSHD. The discovery that pathogenic
         <em>
          SMCHD1, DNMT3B
         </em>
         and
         <em>
          LRIF1
         </em>
         variants cause FSHD2 has led to commercial availability of molecular genetic testing for FSHD2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the absence of haplotype analysis, a false positive result can occur if the contracted D4Z4 array is located on the non-permissive 4qB haplotype. Thus, it is important to know if the genetic testing includes haplotype analysis with the ability to distinguish whether the contracted D4Z4 is located on 4qA or 4qB [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although most patients with FSHD have one contracted D4Z4 allele with 1 to 10 repeat units, there is no definitive cut-off for the number of repeats that unequivocally establish the diagnosis [
         <a href="#rid6">
          6
         </a>
         ]. A D4Z4 locus with 10 or 11 repeats should be considered borderline and interpreted in the context of clinical suspicion for the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The sensitivity of genetic testing for atypical FSHD cases (see
         <a class="local">
          'Atypical forms'
         </a>
         above) remains uncertain [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Novel techniques that may facilitate the genetic diagnosis of FSHD are under development [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H87347580">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuromuscular conditions that can be confused with FSHD include the following [
         <a href="#rid6">
          6,75
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scapuloperoneal syndromes, particularly myotonic dystrophy type 1 and type 2 (see
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb girdle muscular dystrophy (see
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polymyositis (see
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inclusion body myositis and autosomal recessive inclusion body myopathy (see
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mitochondrial myopathies (see
         <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">
          "Mitochondrial myopathies: Clinical features and diagnosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital myopathies (see
         <a class="medical medical_review" href="/z/d/html/6150.html" rel="external">
          "Congenital myopathies"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juvenile and adult forms of acid maltase deficiency (see
         <a class="medical medical_review" href="/z/d/html/2905.html" rel="external">
          "Lysosomal acid alpha-glucosidase deficiency (Pompe disease, glycogen storage disease II, acid maltase deficiency)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The clinical pattern of muscle weakness and histopathologic findings for the scapuloperoneal syndromes, myotonic dystrophy, and limb-girdle muscular dystrophies may not be easily distinguished from FSHD. In such cases, the definitive diagnosis requires molecular genetic testing [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The remaining conditions (polymyositis, inclusion body myositis and autosomal recessive inclusion body myopathy, mitochondrial myopathies, congenital myopathies and acid maltase deficiency) can usually be distinguished from FSHD based on their distinct muscle histopathology [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H263587926">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of FSHD is primarily supportive, as no disease-modifying therapy is available. Recommendations regarding management are based more on consensus and clinical experience than on evidence from randomized trials. The main focus of management involves physical therapy and rehabilitation, exercise, pain control, and orthopedic interventions [
         <a href="#rid75">
          75,77
         </a>
         ]. Other issues requiring surveillance include potential pulmonary, ophthalmologic, and auditory problems related to FSHD. Cardiac evaluation is needed for those who develop overt symptoms or signs of cardiac disease but routine screening is not otherwise necessary [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196284905">
         <span class="h2">
          Physical therapy and rehabilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with FSHD and functional limitations may benefit from a physical therapy and rehabilitation consultation with assessment of posture, gait, and the need for exercise, stretching, assistive devices, and orthopedic interventions [
         <a href="#rid75">
          75
         </a>
         ]. Patients with mild disease may need only yearly follow-up. Those with severe disease and disability, particularly those with severe early-onset forms of FSHD, may benefit from ongoing physical, occupational, and speech therapy.
        </p>
        <p class="headingAnchor" id="H196284933">
         <span class="h2">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although data are limited, the available evidence suggests that exercise is not harmful for patients with FSHD [
         <a href="#rid88">
          88,89
         </a>
         ], and that aerobic exercise is beneficial in terms of improved cardiovascular fitness and strength [
         <a href="#rid90">
          90,91
         </a>
         ]. These findings led an expert panel to recommend that patients with FSHD engage in aerobic training at least three times a week for 30 minutes per session at an intensity to reach the age-adjusted target heart rate for aerobic fitness [
         <a href="#rid75">
          75
         </a>
         ]. For patients who cannot participate in aerobic exercise, the expert panel recommended a moderate intensity resistance training program. Similarly, 2015 guidelines from the American Academy of Neurology (AAN) and the American Association of Neuromuscular &amp; Electrodiagnostic Medicine (AANEM) state that clinicians might encourage low-intensity aerobic exercise for patients with FSHD [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196285062">
         <span class="h2">
          Orthopedic interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because the deltoid muscles are usually preserved, patients with significant weakness may show some improvement in abduction and flexion of the upper arm with surgical fixation of the scapulae to the posterior part of the thorax [
         <a href="#rid92">
          92-95
         </a>
         ]. Scapulothoracic fusion can also relieve shoulder pain and fatigue, and improve the appearance of the neck and shoulder in patients with FSHD who have symptomatic scapular winging. Since loss of scapular fixation may recur after surgery, we suggest surgery on one side and, if successful, consideration of fixation on the opposite side. Wrist and ankle supports may also be useful. The 2015 AAN/AANEM guidelines note that surgical scapular fixation "might be cautiously offered to selected patients" with FSHD after accounting for individual characteristics, including the potential gain in range of motion by manual fixation of the scapula, the rate of disease progression, and the potential adverse effects of surgery and postsurgical bracing [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H196285094">
         <span class="h2">
          Pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain is a common problem in FSHD (see
         <a class="local">
          'Other manifestations'
         </a>
         above) and is generally managed with physical therapy, exercise, and a wide variety of analgesic medications [
         <a href="#rid36">
          36,39
         </a>
         ]. The 2015 AAN/AANEM guidelines recommend that practitioners routinely inquire about musculoskeletal pain in FSHD, and note that a trial of nonsteroidal anti-inflammatory medications is appropriate for acute pain, while antidepressants or antiepileptics are appropriate for chronic pain [
         <a href="#rid77">
          77
         </a>
         ]. However, pain control in FSHD is poorly studied.
        </p>
        <p class="headingAnchor" id="H196288678">
         <span class="h2">
          Respiratory surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory insufficiency is rare, but approximately 1 percent of patients with FSHD may require nocturnal ventilatory support, usually decades after disease onset [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In accord with the 2015 AAN/AANEM guidelines [
         <a href="#rid77">
          77
         </a>
         ], we recommend baseline pulmonary function tests with supine and sitting forced vital capacity (FVC) measurements for all patients diagnosed with FSHD. We also suggest routine pulmonary monitoring (eg, yearly pulmonary function tests) for patients with any of the following conditions [
         <a href="#rid75">
          75,77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal baseline pulmonary function test results
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe proximal weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kyphoscoliosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lumbar hyperlordosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest wall deformities such as pectus excavatum
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wheelchair dependence
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic obstructive pulmonary disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac disease
        </p>
        <p>
        </p>
        <p>
         Patients with FSHD who do not fulfill these conditions should nevertheless have pulmonary function testing prior to any procedure requiring general anesthesia or conscious sedation [
         <a href="#rid75">
          75,77
         </a>
         ].
        </p>
        <p>
         Respiratory insufficiency initially may manifest during sleep [
         <a href="#rid77">
          77
         </a>
         ]. Thus, the 2015 AAN/AANEM guidelines recommend pulmonary or sleep medicine evaluation and consideration of nocturnal sleep monitoring or nocturnal noninvasive ventilation for patients with FSHD who have either of the following [
         <a href="#rid77">
          77
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal pulmonary function studies (eg, forced vital capacity &lt;60 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of excessive daytime somnolence or nonrestorative sleep (eg, frequent nocturnal arousals, morning headaches)
        </p>
        <p>
        </p>
        <p>
         The evaluation and management of respiratory muscle weakness due to neuromuscular disease is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5121.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5124.html" rel="external">
          "Respiratory muscle weakness due to neuromuscular disease: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H196288869">
         <span class="h2">
          Eye care
         </span>
         <span class="headingEndMark">
          —
         </span>
         A dilated retinal examination by ophthalmoscopy is recommended at the time of diagnosis for all patients with FSHD to look for evidence of retinal vascular disease and Coats syndrome (see
         <a class="local">
          'Other manifestations'
         </a>
         above), which is usually treatable with photocoagulation of the abnormal vessels [
         <a href="#rid75">
          75
         </a>
         ]. Photocoagulation, if done early, is thought to be effective in preventing retinal damage and detachment of the retina.
        </p>
        <p>
         The frequency of subsequent monitoring can be determined by the presence and severity of retinal vascular disease at the initial screening [
         <a href="#rid77">
          77
         </a>
         ]. No further follow-up is needed for adults if vascular disease is absent unless visual symptoms arise. Annual follow-up is recommended for children with early onset of FSHD, at least until the child is mature enough to report visual symptoms. Closer surveillance is suggested for patients with D4Z4 repeat array fragments ≤15 kb in size [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         In some patients with FSHD, facial weakness can lead to exposure keratitis if the eyes remain partially open during sleep [
         <a href="#rid6">
          6
         </a>
         ]. To prevent drying of the sclera, ophthalmic ointments and eye patches can be used at night. However, tape should not be placed directly on the eyelid since the patch could slip and abrade the cornea.
        </p>
        <p class="headingAnchor" id="H196289208">
         <span class="h2">
          Hearing loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         The infantile form of FSHD may be associated with an increased risk of hearing loss (see
         <a class="local">
          'Other manifestations'
         </a>
         above), leading to the recommendation to test hearing in infants and preschool-aged children with FSHD at baseline and yearly thereafter [
         <a href="#rid75">
          75,77
         </a>
         ]. Routine school-based hearing assessments are sufficient for school-aged children with FSHD and normal language development. Adults with FSHD do not need hearing evaluations unless they have symptoms.
        </p>
        <p class="headingAnchor" id="H263593979">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Progression of FSHD is typically slow and most studies suggest that the life span is not significantly affected [
         <a href="#rid6">
          6,27
         </a>
         ]. In some cases, patients remain asymptomatic or have minimal symptoms throughout their life. In other cases, rapid or stuttering deterioration leads to significant disability. A number of studies have found that individuals with large D4Z4 contractions resulting in a small repeat (one to three residual repeats) tend to have earlier onset disease and faster progression than those with smaller D4Z4 contractions [
         <a href="#rid69">
          69,74,81,96-98
         </a>
         ].
        </p>
        <p>
         Eventual wheelchair dependence occurs in approximately 20 percent of patients. In one study that prospectively followed 81 patients with FSHD for over three years, there was a slow but detectable decrease in muscle strength over time that was not associated with age, sex, age at symptom onset, or disease duration [
         <a href="#rid99">
          99
         </a>
         ]. However, patients with early onset and a longer duration tend to have more clinical symptoms [
         <a href="#rid98">
          98
         </a>
         ]. Some reports suggest that men with FSHD are more severely affected than women [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H263595677">
         <span class="h2">
          Pregnancy outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data regarding pregnancy outcomes in women with FSHD. In a survey of 38 women with FSHD that included 105 gestations and 78 live births, pregnancy outcomes were generally favorable [
         <a href="#rid102">
          102
         </a>
         ]. However, both the rate of low birth weight and the combined rate for all operative vaginal deliveries were significantly higher than expected in the general population. Further, worsening of FSHD symptoms was observed in 24 percent of the pregnancies, usually without return to baseline after delivery.
        </p>
        <p class="headingAnchor" id="H984363715">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121073.html" rel="external">
          "Society guideline links: Muscular dystrophy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H263593057">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15489.html" rel="external">
          "Patient education: Muscular dystrophy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/725.html" rel="external">
          "Patient education: Overview of muscular dystrophies (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H263593306">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Facioscapulohumeral muscular dystrophy (FSHD) is a complex genetic disorder characterized in most cases by slowly progressive muscle weakness involving the facial, scapular, upper arm, lower leg, and hip girdle muscles. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – The probable cause of FSHD is inappropriate expression of the
         <em>
          DUX4
         </em>
         gene. Different pathways (D4Z4 repeat contractions in FSHD1  (
         <a class="graphic graphic_figure graphicRef129048" href="/z/d/graphic/129048.html" rel="external">
          figure 2
         </a>
         ) and heterozygous pathogenic
         <em>
          SMCHD1
         </em>
         variants in FSHD2) lead to D4Z4 chromatin relaxation ("unwinding" of the DNA) and abnormal expression of
         <em>
          DUX4
         </em>
         . (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – FSHD is the third most common type of muscular dystrophy. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The typical or classic form of FSHD is characterized by muscle weakness involving the facial, scapular, upper arm, lower leg, and abdominal muscles, usually with asymmetric involvement. The age of symptom onset is usually in the second decade. By age 20 years, findings are seen in approximately 90 percent of affected patients, although some or all the signs may be subclinical. Progression is ordinarily slow. However, progression and disease severity are highly variable. Other manifestations of FSHD may include pain, retinal vasculopathy, hearing loss, cardiac arrhythmia, cognitive impairment, and epilepsy. FSHD1 and FSHD2 are clinically indistinguishable. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical and infantile forms
         </strong>
         – Several atypical variants of FSHD are recognized, including infantile or early onset FSHD. (See
         <a class="local">
          'Atypical forms'
         </a>
         above and
         <a class="local">
          'Infantile form'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The diagnosis of typical FSHD is suspected in patients who present with weakness of the face, shoulder girdle, and upper arm with relative sparing of the deltoid muscles. Genetic testing is the principle method for confirming the diagnosis  (
         <a class="graphic graphic_algorithm graphicRef103638" href="/z/d/graphic/103638.html" rel="external">
          algorithm 1
         </a>
         ). Electromyography (EMG) and/or muscle biopsy are used infrequently in cases with atypical phenotypes and negative genetic testing for FSHD1 and FSHD2. In general, patients with suspected muscular dystrophy should be referred to a specialist with expertise in neuromuscular disorders for evaluation and diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – The management of FSHD is primarily supportive, as no disease-modifying therapy is available. The main focus of management involves physical therapy and rehabilitation, exercise, pain control, and orthopedic interventions. Other issues requiring surveillance include potential pulmonary, ophthalmologic, and auditory problems related to FSHD. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hamel J, Tawil R. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments. Neurotherapeutics 2018; 15:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mul K. Facioscapulohumeral Muscular Dystrophy. Continuum (Minneap Minn) 2022; 28:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 2011; 17:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schätzl T, Kaiser L, Deigner HP. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. Orphanet J Rare Dis 2021; 16:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 2010; 329:1650.
          </a>
         </li>
         <li class="breakAll">
          Lemmers RJ, Miller DG, van der Maarel SM. Facioscapulohumeral muscular dystrophy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1443/ (Accessed on November 15, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards M, Coppée F, Thomas N, et al. Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled? Hum Genet 2012; 131:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol 2011; 24:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 2003; 35:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng W, de Greef JC, Chen YY, et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 2009; 5:e1000559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zheng F, Qiu L, Chen L, et al. Association of 4qA-Specific Distal D4Z4 Hypomethylation With Disease Severity and Progression in Facioscapulohumeral Muscular Dystrophy. Neurology 2023; 101:e225.
          </a>
         </li>
         <li class="breakAll">
          Liew WK, van der Maarel SM, Tawil R. Facioscapulohumeral dystrophy. In: Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach, 2, Darras BT, Jones HR Jr, Ryan MM, De Vivo DC (Eds), Academic Press, San Diego 2015. p.620.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmers RJ, Goeman JJ, van der Vliet PJ, et al. Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Hum Mol Genet 2015; 24:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nat Genet 2012; 44:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacconi S, Lemmers RJ, Balog J, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 2013; 93:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacconi S, Briand-Suleau A, Gros M, et al. FSHD1 and FSHD2 form a disease continuum. Neurology 2019; 92:e2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Boogaard ML, Lemmers RJLF, Balog J, et al. Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. Am J Hum Genet 2016; 98:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamanaka K, Šikrová D, Mitsuhashi S, et al. Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy. Neurology 2020; 94:e2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Greef JC, Lemmers RJ, Camaño P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 2010; 75:1548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen M, Rost S, El Hajj N, et al. Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1. Eur J Hum Genet 2015; 23:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhler J, Rupilius B, Otto M, et al. Germline mosaicism in 4q35 facioscapulohumeral muscular dystrophy (FSHD1A) occurring predominantly in oogenesis. Hum Genet 1996; 98:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker E, Van der Wielen MJ, Voorhoeve E, et al. Diagnostic, predictive, and prenatal testing for facioscapulohumeral muscular dystrophy: diagnostic approach for sporadic and familial cases. J Med Genet 1996; 33:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mostacciuolo ML, Pastorello E, Vazza G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet 2009; 75:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sposìto R, Pasquali L, Galluzzi F, et al. Facioscapulohumeral muscular dystrophy type 1A in northwestern Tuscany: a molecular genetics-based epidemiological and genotype-phenotype study. Genet Test 2005; 9:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanigan KM, Coffeen CM, Sexton L, et al. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001; 11:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deenen JC, Arnts H, van der Maarel SM, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology 2014; 83:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orrell RW. Facioscapulohumeral dystrophy and scapuloperoneal syndromes. Handb Clin Neurol 2011; 101:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mul K, Lassche S, Voermans NC, et al. What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol 2016; 16:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohlgemuth M, de Swart BJ, Kalf JG, et al. Dysphagia in facioscapulohumeral muscular dystrophy. Neurology 2006; 66:1926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wicklund MP. The muscular dystrophies. Continuum (Minneap Minn) 2013; 19:1535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohlgemuth M, van der Kooi EL, van Kesteren RG, et al. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology 2004; 63:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scully MA, Eichinger KJ, Donlin-Smith CM, et al. Restrictive lung involvement in facioscapulohumeral muscular dystrophy. Muscle Nerve 2014; 50:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henke C, Spiesshoefer J, Kabitz HJ, et al. Respiratory muscle weakness in facioscapulohumeral muscular dystrophy. Muscle Nerve 2019; 60:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Runte M, Spiesshoefer J, Heidbreder A, et al. Sleep-related breathing disorders in facioscapulohumeral dystrophy. Sleep Breath 2019; 23:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Kooi EL, Kalkman JS, Lindeman E, et al. Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J Neurol 2007; 254:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen MP, Hoffman AJ, Stoelb BL, et al. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med Rehabil 2008; 89:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padua L, Aprile I, Frusciante R, et al. Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve 2009; 40:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morís G, Wood L, FernáNdez-Torrón R, et al. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy. Muscle Nerve 2018; 57:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bushby KM, Pollitt C, Johnson MA, et al. Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord 1998; 8:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padberg GW, Brouwer OF, de Keizer RJ, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl 1995; 2:S73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain 1987; 110 ( Pt 3):631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghorbanian S, Jaulim A, Chatziralli IP. Diagnosis and treatment of coats' disease: a review of the literature. Ophthalmologica 2012; 227:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Statland JM, Sacconi S, Farmakidis C, et al. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology 2013; 80:1247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass SJ, Sherman J, Giovinazzo V. Bilateral Coats' response in a female patient leads to diagnosis of facioscapulohumeral muscular dystrophy. Optometry 2011; 82:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouwer OF, Padberg GW, Ruys CJ, et al. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology 1991; 41:1878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lutz KL, Holte L, Kliethermes SA, et al. Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy. Neurology 2013; 81:1374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers MT, Zhao F, Harper PS, Stephens D. Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2002; 12:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trevisan CP, Pastorello E, Ermani M, et al. Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function. Audiol Neurootol 2008; 13:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol 1990; 15:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laforêt P, de Toma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology 1998; 51:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trevisan CP, Pastorello E, Armani M, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. Eur Neurol 2006; 56:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galetta F, Franzoni F, Sposito R, et al. Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2005; 15:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Visser M, de Voogt WG, la Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992; 15:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology 1998; 50:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuzaka T, Sakuragawa N, Terasawa K, Kuwabara H. Facioscapulohumeral dystrophy associated with mental retardation, hearing loss, and tortuosity of retinal arterioles. J Child Neurol 1986; 1:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miura K, Kumagai T, Matsumoto A, et al. Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy. Neuropediatrics 1998; 29:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito Y, Miyashita S, Yokoyama A, et al. Facioscapulohumeral muscular dystrophy with severe mental retardation and epilepsy. Brain Dev 2007; 29:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felice KJ, North WA, Moore SA, Mathews KD. FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy. Neurology 2000; 54:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jardine PE, Upadhyaya M, Maynard J, et al. A scapular onset muscular dystrophy without facial involvement: possible allelism with facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1994; 4:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasnianski M, Eger K, Neudecker S, et al. Atypical phenotypes in patients with facioscapulohumeral muscular dystrophy 4q35 deletion. Arch Neurol 2003; 60:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilich P, Schramm N, Schoser B, et al. Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy. J Neurol 2010; 257:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felice KJ, Moore SA. Unusual clinical presentations in patients harboring the facioscapulohumeral dystrophy 4q35 deletion. Muscle Nerve 2001; 24:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Kooi AJ, Visser MC, Rosenberg N, et al. Extension of the clinical range of facioscapulohumeral dystrophy: report of six cases. J Neurol Neurosurg Psychiatry 2000; 69:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uncini A, Galluzzi G, Di Muzio A, et al. Facioscapulohumeral muscular dystrophy presenting isolated monomelic lower limb atrophy. Report of two patients with and without 4q35 rearrangement. Neuromuscul Disord 2002; 12:874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassan A, Jones LK Jr, Milone M, Kumar N. Focal and other unusual presentations of facioscapulohumeral muscular dystrophy. Muscle Nerve 2012; 46:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood-Allum C, Brennan P, Hewitt M, et al. Clinical and histopathological heterogeneity in patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD). Neuropathol Appl Neurobiol 2004; 30:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottlors M, Kress W, Meng G, Glocker FX. Facioscapulohumeral muscular dystrophy presenting with isolated axial myopathy and bent spine syndrome. Muscle Nerve 2010; 42:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan B, Eger K, Koesling S, Zierz S. Camptocormia phenotype of FSHD: a clinical and MRI study on six patients. J Neurol 2011; 258:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinge L, Eagle M, Haggerty ID, et al. Severe phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2006; 16:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouwer OF, Padberg GW, Wijmenga C, Frants RR. Facioscapulohumeral muscular dystrophy in early childhood. Arch Neurol 1994; 51:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felice KJ, Jones JM, Conway SR. Facioscapulohumeral dystrophy presenting as infantile facial diplegia and late-onset limb-girdle myopathy in members of the same family. Muscle Nerve 2005; 32:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouwer OF, Padberg GW, Bakker E, et al. Early onset facioscapulohumeral muscular dystrophy. Muscle Nerve Suppl 1995; 2:S67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okinaga A, Matsuoka T, Umeda J, et al. Early-onset facioscapulohumeral muscular dystrophy: two case reports. Brain Dev 1997; 19:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bindoff LA, Mjellem N, Sommerfelt K, et al. Severe fascioscapulohumeral muscular dystrophy presenting with Coats' disease and mental retardation. Neuromuscul Disord 2006; 16:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 2010; 20:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmers RJ, O'Shea S, Padberg GW, et al. Best practice guidelines on genetic diagnostics of Facioscapulohumeral muscular dystrophy: workshop 9th June 2010, LUMC, Leiden, The Netherlands. Neuromuscul Disord 2012; 22:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2015; 85:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awerbuch GI, Nigro MA, Wishnow R. Beevor's sign and facioscapulohumeral dystrophy. Arch Neurol 1990; 47:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahrizaila N, Wills AJ. Significance of Beevor's sign in facioscapulohumeral dystrophy and other neuromuscular diseases. J Neurol Neurosurg Psychiatry 2005; 76:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köhler J, Röhrig D, Bathke KD, Koch MC. Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments. Clin Genet 1999; 55:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol 1999; 45:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitelli F, Villanova M, Malandrini A, et al. Inheritance of a 38-kb fragment in apparently sporadic facioscapulohumeral muscular dystrophy. Muscle Nerve 1999; 22:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdmann H, Scharf F, Gehling S, et al. Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy. Brain 2023; 146:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lemmers RJ, Osborn M, Haaf T, et al. D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection. Neurology 2003; 61:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deak KL, Lemmers RJ, Stajich JM, et al. Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4. Neurology 2007; 68:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacconi S, Salviati L, Bourget I, et al. Diagnostic challenges in facioscapulohumeral muscular dystrophy. Neurology 2006; 67:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrlich M, Jackson K, Tsumagari K, et al. Hybridization analysis of D4Z4 repeat arrays linked to FSHD. Chromosoma 2007; 116:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milner-Brown HS, Miller RG. Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 1988; 69:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 2004; 63:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen DB, Ørngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology 2005; 64:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen G, Prahm KP, Dahlqvist JR, et al. Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy: RCT study. Neurology 2015; 85:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diab M, Darras BT, Shapiro F. Scapulothoracic fusion for facioscapulohumeral muscular dystrophy. J Bone Joint Surg Am 2005; 87:2267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini S, Ceccarelli F, Faldini C, et al. Scapulopexy of winged scapula secondary to facioscapulohumeral muscular dystrophy. Clin Orthop Relat Res 2006; 449:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orrell RW, Copeland S, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev 2010; :CD003278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Tongel A, Atoun E, Narvani A, et al. Medium to long-term outcome of thoracoscapular arthrodesis with screw fixation for facioscapulohumeral muscular dystrophy. J Bone Joint Surg Am 2013; 95:1404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Statland JM, Tawil R. Risk of functional impairment in Facioscapulohumeral muscular dystrophy. Muscle Nerve 2014; 49:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol 1996; 39:744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz NK, Hogan J, Delbango R, et al. Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy. Brain 2021; 144:3451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group. Neurology 1997; 48:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zatz M, Marie SK, Cerqueira A, et al. The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females. Am J Med Genet 1998; 77:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tonini MM, Passos-Bueno MR, Cerqueira A, et al. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul Disord 2004; 14:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciafaloni E, Pressman EK, Loi AM, et al. Pregnancy and birth outcomes in women with facioscapulohumeral muscular dystrophy. Neurology 2006; 67:1887.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 87096 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30361930" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36537978" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Facioscapulohumeral Muscular Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21288772" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33712050" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20724583" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A unifying genetic model for facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20724583" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A unifying genetic model for facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21984394" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734574" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634647" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19593370" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37225433" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Association of 4qA-Specific Distal D4Z4 Hypomethylation With Disease Severity and Progression in Facioscapulohumeral Muscular Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37225433" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Association of 4qA-Specific Distal D4Z4 Hypomethylation With Disease Severity and Progression in Facioscapulohumeral Muscular Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25256356" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143600" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24075187" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30979860" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : FSHD1 and FSHD2 form a disease continuum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27153398" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32467133" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20975055" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical features of facioscapulohumeral muscular dystrophy 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25370034" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8792827" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Germline mosaicism in 4q35 facioscapulohumeral muscular dystrophy (FSHD1A) occurring predominantly in oogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8825045" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diagnostic, predictive, and prenatal testing for facioscapulohumeral muscular dystrophy: diagnostic approach for sporadic and familial cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19320656" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15857184" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Facioscapulohumeral muscular dystrophy type 1A in northwestern Tuscany: a molecular genetics-based epidemiological and genotype-phenotype study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11525880" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25122204" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Population-based incidence and prevalence of facioscapulohumeral dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21496633" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Facioscapulohumeral dystrophy and scapuloperoneal syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26862222" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : What's in a name? The clinical features of facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16801662" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dysphagia in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24305447" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The muscular dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15249635" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ventilatory support in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24639337" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Restrictive lung involvement in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31566774" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Respiratory muscle weakness in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31025273" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sleep-related breathing disorders in facioscapulohumeral dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17361345" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18226657" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19609906" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Quality of life and pain in patients with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29053898" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10093064" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7739630" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3580827" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22440929" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Diagnosis and treatment of coats' disease: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23446679" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21130700" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bilateral Coats' response in a female patient leads to diagnosis of facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1745341" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hearing loss in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24042093" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical and genetic features of hearing loss in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12062253" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Absence of hearing impairment in adult onset facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17715463" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Facioscapulohumeral muscular dystrophy: a multicenter study on hearing function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2299071" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9818880" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16804309" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15907286" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1584251" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9633729" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3598127" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Facioscapulohumeral dystrophy associated with mental retardation, hearing loss, and tortuosity of retinal arterioles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9810558" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular dystrophy with mental retardation and epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17010549" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Facioscapulohumeral muscular dystrophy with severe mental retardation and epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10822431" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7881292" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A scapular onset muscular dystrophy without facial involvement: possible allelism with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14568813" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Atypical phenotypes in patients with facioscapulohumeral muscular dystrophy 4q35 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20146070" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Facioscapulohumeral muscular dystrophy presenting with unusual phenotypes and atypical morphological features of vacuolar myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353419" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Unusual clinical presentations in patients harboring the facioscapulohumeral dystrophy 4q35 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10864616" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Extension of the clinical range of facioscapulohumeral dystrophy: report of six cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12398841" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Facioscapulohumeral muscular dystrophy presenting isolated monomelic lower limb atrophy. Report of two patients with and without 4q35 rearrangement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22907234" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Focal and other unusual presentations of facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15043716" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical and histopathological heterogeneity in patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20658601" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Facioscapulohumeral muscular dystrophy presenting with isolated axial myopathy and bent spine syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21165637" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Camptocormia phenotype of FSHD: a clinical and MRI study on six patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16934468" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Severe phenotype in infantile facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8155016" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Facioscapulohumeral muscular dystrophy in early childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880682" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Facioscapulohumeral dystrophy presenting as infantile facial diplegia and late-onset limb-girdle myopathy in members of the same family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7739629" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Early onset facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440803" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Early-onset facioscapulohumeral muscular dystrophy: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16935506" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Severe fascioscapulohumeral muscular dystrophy presenting with Coats' disease and mental retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20554202" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22177830" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Best practice guidelines on genetic diagnostics of Facioscapulohumeral muscular dystrophy: workshop 9th June 2010, LUMC, Leiden, The Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26215877" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular&amp;Electrodiagnostic Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2146943" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Beevor's sign and facioscapulohumeral dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897515" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Significance of Beevor's sign in facioscapulohumeral dystrophy and other neuromuscular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10189085" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Evaluation of the facioscapulohumeral muscular dystrophy (FSHD1) phenotype in correlation to the concurrence of 4q35 and 10q26 fragments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10360767" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487912" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Inheritance of a 38-kb fragment in apparently sporadic facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36100962" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Methylation of the 4q35 D4Z4 repeat defines disease status in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874395" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : D4F104S1 deletion in facioscapulohumeral muscular dystrophy: phenotype, size, and detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17229919" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17060574" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Diagnostic challenges in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17131163" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Hybridization analysis of D4Z4 repeat arrays linked to FSHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3337636" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Muscle strengthening through high-resistance weight training in patients with neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15326246" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Strength training and albuterol in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781829" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26156512" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy: RCT study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16203893" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Scapulothoracic fusion for facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16672903" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Scapulopexy of winged scapula secondary to facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091543" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Scapular fixation in muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23925745" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Medium to long-term outcome of thoracoscapular arthrodesis with screw fixation for facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23873337" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Risk of functional impairment in Facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8651646" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34542603" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9008491" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605290" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The facioscapulohumeral muscular dystrophy (FSHD1) gene affects males more severely and more frequently than females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14659410" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130433" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Pregnancy and birth outcomes in women with facioscapulohumeral muscular dystrophy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
